regeneron

Appeal could throw spanner in the works for Regeneron’s Irish expansion

pharmafile | March 9, 2018 | News story | Manufacturing and Production, Medical Communications Ireland, Regeneron, pharma 

Regeneron is facing a single man-sized obstacle in plans to expand operations at its campus in Limerick, Ireland with a new €20 million bulk biologics facility which could see delays of up to half a year.  

One Michael Fenton has applied to independent Irish judicial body An Bord Pleanála to appeal the green light given by Limerick County Council. He did not object to the plans earlier in the process when the project was put before the council.  

The US firm originally announced the plans in October last year. It has stated that the expansion will create 150 new permanent roles, made up of those from the local area as well as people relocating back to Ireland. Additionally, the company said that 137 roles would be created in the service industry, while the three-year construction project to build the new site would employ another 500 people.

Advertisement

The board is due to make a decision on the matter by the end of March, and it could mean the project could be delayed by four to six months if the ruling comes down on the side of Mr Fenton.

Matt Fellows

Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

clinical_trials

Dupixent improves symptoms in patients with skin of colour, study shows

Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at …

The Gateway to Local Adoption Series

Latest content